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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
intranasal ketorolac is both safe and effective in reducing acute postoperative pain for patients
over 18 years of age that require inpatient hospitalization.
STUDY DESIGN: Review of three double-blind randomized controlled trials (RCTs) were used,
all are from 2008 to present and all are in the English language.
DATA SOURCES: Data sources include articles that were published on both PubMed and
Cochrane databases and were selected based on their relevance to the research question as well
as patient measured outcomes.
OUTCOMES MEASURED: Outcomes measured include efficacy of the drug measured through
Visual Analog Scale (VAS), Pain Intensity Differences (PID) and Summed Pain Intensity
Differences at 6 hours (SPID6) as well as safety measured through self-reported adverse events
or change in clinical status.
RESULTS: The study by Moodie et al.6 showed a significant increase of 64.9 (p=0.0015) in
SPID6 scores between intranasal ketorolac and placebo. Brown et al.7 also showed a significant
increase of 46.1 (p=0.007) in the SPID6 scores between the groups. Finally, Singla et al.8
additionally demonstrated a significant increase of 27.6 (p=0.03) in SPID6 scores between the
two groups.
CONCLUSIONS: All three studies demonstrated that intranasal ketorolac is both safe and
effective in reducing pain postoperatively.
KEY WORDS: Intranasal ketorolac; postoperative pain
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INTRODUCTION
Postoperative pain is one of the most common side effects that follows a surgical
procedure and can also be one of the most challenging to manage. As many as 80% of patients
admit to acute pain after surgery but under 50% report sufficient pain control before and after
discharge.1 Long term consequences of inadequately controlled pain can include increased postsurgical complications, decreased quality of life and persistent chronic pain.1 The estimated
economic burden of pain cost the United States between $560-$665 billion, including lost
productivity and healthcare costs, which was reported in 2010.2 The exact number of healthcare
visits per year is unknown, however, about 10.3 million inpatient surgeries were performed in
2014 so an estimated 8.2 million stays per year would have required post-operative pain
management.3
Pain is a broad definition that describes the body’s physiological response to nerve
stimulation or tissue damage and involves both physical and emotional responses from the body.4
Although the pain pathway is quite complex, tissue damage from injury or surgery triggers
nociceptors in the nerve endings to send electrical signals to the brain. These electrical signals
are received to the brain on varying intensities based on their threat to the tissue.4 The brain will
then send adaptive responses to the tissue, such as reflex mechanisms and/or inflammatory
mediators, to prevent further injury and start repairing the damage. Acute pain occurs from some
known direct insult to the body, such as an injury or surgical procedure.4 Chronic pain occurs
over months or even years at a time and can occur from improperly controlled acute pain even
once the original injury has healed.4 Each individual experiences and perceives pain differently
and can lead to various challenges when properly treating and managing acute pain
postoperatively.
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Adequately controlling acute pain postoperatively through analgesic therapy is key in
order to prevent stressful physiologic responses and adverse health consequences. For example,
if patients are in too much pain to get out of bed and ambulate after surgery, they are at a
significantly higher risk for acquiring complications such as blood clots, pneumonia, atelectasis,
etc.5 The mainstay of treatment for postoperative pain is opioid analgesics; this can be given
intravenously (IV), such as through patient-controlled analgesic (PCA) pumps, or given orally.5
Some of the most common opioid analgesics used are morphine, fentanyl, hydromorphone, and
hydrocodone.5 Other nonnarcotic oral or IV drugs given alone or in combination with opioids to
control pain include acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS), and/or
gabapentin.5 Epidural or peripheral nerve infusion can also be given to control pain for certain
procedures that involve larger areas of nerve involvement, such as abdominal procedures.5
Practitioners must be mindful when prescribing narcotic medications due to the
possibility of over-sedating their patients, which can lead to potentially fatal side effects such as
respiratory depression and apnea.5 Opioid medications are also highly addictive leading to
regulation and hesitation by health care providers when prescribing narcotic medication,
especially long term. Ketorolac is a non-steroidal anti-inflammatory medication that has been
proven to provide potent analgesic effects, similar to morphine, to control moderate to severe
pain after surgery.6,7,8 The intranasal (IN) route provides additional benefits since it is quickly
absorbed into the bloodstream but does not require an intravenous line to be administered.6,7,8
OBJECTIVE
The objective of this selective EBM review is to determine whether or not intranasal (IN)
ketorolac is both safe and effective in reducing acute postoperative pain for patients over 18
years of age that require inpatient hospitalization.
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METHODS
The studies selected for this EBM review were found using PubMed and Cochrane
Library databases to incorporate three placebo-controlled, double-blind RCTs that included
adults over the age of 18 that were undergoing surgery with inpatient postoperative care. The
intervention being observed in each study was intranasal ketorolac; Moodie et al.6 and Brown et
al.7 used 30 mg of IN ketorolac in a 100 µL solution while Singla et al.8 used 31.5 mg of IN
ketorolac in a 100 µL solution. All studies were compared to a matched placebo that was similar
in container shape, medication color, and administration. Patients still had access to morphine for
pain and could receive back-up pain medication if study drug was not adequate for pain control.
Outcomes measured in these studies was efficacy in pain reduction through summed pain
intensity differences at 6 hours (SPID6) taken through patient reported visual analog scales
(VAS) for pain and pain intensity differences (PID) as well as safety through reports of adverse
events or change in clinical state.
All three RCTs were found in peer-reviewed journals and were published in English
during or after 2007. Articles were then selected based on relevance to the clinical question and
if their results focused on patient-oriented outcomes (POEMS). Inclusion and exclusion criteria
for this review were applied to all three articles. Inclusion criteria were adults over 18 years of
age that underwent an inpatient surgical procedure that required subsequent inpatient care and
pain management. Exclusion criteria included subjects under 18 years of age and studies that
comprised of other treatment modalities other than standard of care compared to the study drug.
Table 1 demonstrates all specific inclusion and exclusion criteria for each study. Values reported
for pain reduction were given in p-values in all three studies while a CI was given for Singla et
al.8 and safety was reported by calculating number needed to harm (NNH) for each study.
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Table 1. Demographics & Characteristics of included studies
Study

Typ #
e
Pts
RCT 84

Age

Inclusion
Criteria

> 18
years
of age
(mea
n age
53)

-Over 18 years old
and weighing
between 100 to
300 pounds
-Pain intensity
score >40 mm out
of 100mm (VAS
scale)
-expected
inpatient stay over
48 hours
-Negative
Pregnancy Test
-Willingness to
comply and
complete
posttreatment visit

Brown7
(2009)

RCT 300

Rang
e of
1981
years
old
(mea
n age
52)

Singla8
(2010)

RCT 321

Rang
e of
18-64
years
old
(Mea
n age
46)

Moodie6
(2008)

Exclusion Criteria

W/D

-Allergy, sensitivity or 17
contraindication (CI)
to the use of NSAIDS
(active bleeding/PUD,
renal impairment, etc.)
-Use of any IN
product w/in 24 hours
-Current URI, past or
present cocaine use, or
other respiratory tract
condition or
abnormality that
would interfere with
medication absorption
or reporting adverse
events
-Clinically significant
abnormality on
screening test (w/in
one month)
-Pregnancy or
breastfeeding
- Over 18 years of -Allergy, sensitivity,
90
age undergoing
or CI to NSAIDs or
major surgery and opiate analgesics
expected to stay in -GI bleeding disorder
the hospital for at
-Current URI or other
least 48 hours and conditions that
up to 5 days
interferes with
intranasal absorption
-Use of other IN
products w/in 24 hours
-Pregnancy or
breastfeeding
-Ages 18-64
-Recent or current
20
undergoing major PUD/GI bleeding
abdominal surgery -Allergies, sensitivities
(US and New
or CI to study drugs
Zealand) under
-Current URI that
general analgesia
could interfere with
expected to remain drug absorption
in the hospital for
-Use of any other IN
at least 48 hours
product w/in 24 hours
and up to 5 days
-Pregnancy or
breastfeeding

Interventions
30-mg IN
ketorolac
given to
subjects
every 8 hours
through 40
hours

30-mg IN
ketorolac
administered
three times
daily for up
to 5 days

31.5-mg IN
ketorolac
given every 6
hours for the
first 48 hours
and then up
to 4 times per
day
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OUTCOMES MEASURED
Outcomes measured in all three studies were pain reduction through the VAS, PID and
SPID6 scores while also measuring safety through adverse events (AE). All studies had patients
rate their pain on the VAS with “0” being absolutely no pain and “100” being worst pain
imaginable. Treatment began when their first VAS was greater than or equal to 40 and measured
again at certain time intervals, usually at 30 minutes and then hourly, for a minimum of 6 hours
and up to 2 to 5 days (as needed). The PIDs were then calculated by taking their baseline score
and subtracting their pain score at certain time intervals after the drug was administered. All
weighted PID scores were then analyzed to get the SPID6 results which is a sum of all PID
scores for the first 6 hours. Greater difference in the SPID6 values between IN ketorolac and the
placebo indicates a greater treatment effect. Safety was measured through adverse events
reported by the patients or by change in clinical status (such as vitals, appearance, etc.) and then
measured through NNH.
RESULTS
Three double-blind, placebo-controlled RCTs were evaluated to assess if intranasal
ketorolac is both safe and effective for reducing postoperative pain in patients over 18 years of
age that require inpatient hospitalization. Moodie et al.6 and Brown et al.7 measured 30 mg of IN
ketorolac and Singla et al.8 measured 31.5 mg of IN ketorolac, all to a matched placebo. All
studies also measured adverse events in both groups. Table 1 above provides all inclusion and
exclusion criteria.
In Moodie et al.6 study, 84 subjects were enrolled to either receive placebo or 30 mg IN
ketorolac.6 Baseline characteristics were marginally similar, however, there was a slight trend
toward older, white men in the placebo group compared to the experimental.6 The intervention
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for the experimental group was 30 mg of IN ketorolac (2 x 100 µL of 15% solution).6 Both the
experimental drug and matched placebo were given in an IN metered device to administer 100
µL of aerosolized medication per nostril.6 Nurses on the post-surgical units would educate
patients on correct administration so that they were able to self-administer throughout the study.
General anesthesia was given to all patients prior to and during surgery. All patients had access
to a PCA morphine pumps and rescue opioid medications for pain after surgery though no
subjects requested rescue medications. VAS and PID scores were calculated at multiple time
intervals for two days, but for the purpose of this analysis, only the first 6 hours were included
(at 30 minutes and then 1,2,3,4,5, & 6 hours).6 SPID6 results were analyzed with the KruskalWallis test between the two groups.6 The SPID6 score for the experimental group was 195.5
while the SPID6 score for the placebo group was 130.6 with a difference in SPID6 scores of 64.9
(p= 0.0015).6 Table 2 has a summary of the results below. Safety was also assessed by total
adverse events (AE) and calculating the NNH. AE were compared upon both treatment groups
using the chi-square (χ2) test or Fisher’s exact test, as applicable.6 The IN ketorolac group had a
AE frequency rate of 95.2% while the placebo group has a AE frequency rate of 97.6%.6 Nausea
and pyrexia were the most common AE overall but there was a 28.6% decrease of pyrexia in the
ketorolac group compared to placebo.6 Nasal passage irritation was one of the only AE much
higher in the ketorolac group (16.7%) compared to placebo (11.9%).6 The NNH was calculated
at -50 which means that 1 less patient will experience an adverse event with IN ketorolac
compared to the placebo for every 50 patients treated. Table 3 has the results below.
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Table 2: Mean Baseline VAS Scores and Difference in SPID6 Values
Mean Baseline
VAS Score (SEM)

Experimental
Group
Control Group

52.0 (1.5)
51.4 (1.7)

SPID6 Values
(SEM)
195.5 (12.1)

Difference between
SPID6 Values

P-Value

64.9

P=0.0015

130.6 (14.4)

Table 3: Comparison of Occurrences in Adverse Events between Ketorolac and Placebo
Control event
rate (CER)
0.976

Experiment
event rate (EER)
0.952

Relative risk
increase (RRI)
-0.025

Absolute risk
increase (ARI)
-0.024

Number needed
to harm (NNH)
-50

In Brown et al.7 study, 300 patients were initially enrolled in the study in a 2:1 ratio
(ketorolac to placebo, respectively) but only 210 patients (133/199 in the ketorolac group and
72/101 in the placebo group) completed all 5 days of dosing.7 Most common reasons for
withdrawal were adverse events, concurrent illness and/or lab abnormality (33/199 in ketorolac
group and 14/101 in placebo group).7 A last observation carried forward approach was taken for
the subjects who withdrew early.7 Demographics and vital signs were similar between both
groups. Most patients were middle-aged white women undergoing a total hysterectomy or hip
replacement, though other invasive surgical procedures were included.7 The experimental group
intervention was 30 mg of IN ketorolac (100 µL solution) administered in a meter-pumped spray
delivery system with one spray per nostril.7 The placebo drug was similar in all aspects except
containing the active drug, ketorolac. Study nurses would educate patients on correct
administration so that they were able to self-administer throughout the study when comfortable
to do so. Participants had access to a morphine PCA pump and backup analgesics in this study
while some partook in a single-dose trial without backup analgesics, however, this was not
evaluated in this analysis. The PID ratings were analyzed with one-way analysis of variance
(ANOVA) while the treatment group differences were analyzed with log-rank test.7 PID and
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SPID6 scores were analyzed using analysis of covariance with baseline PI scores.7 The SPID6
scores for the experimental group was 83.3 (+/- 10.6) while the SPID6 scores for the placebo
group was 37.2 (+/-12.9) with a difference of 46.1 (p=0.007).7 Table 4 has data summarized
below. Safety was assessed similarly to the study above through reported AE or change in
clinical status. P-values used to determine differences in AE between the two groups were
calculated with χ2 test.7 The IN ketorolac group had a AE frequency rate of 97.5% while the
placebo group has a AE frequency rate of 98%.7 Nasal irritation, throat irritation, and lacrimation
were higher in the ketorolac group compared to placebo, but pyrexia/intermittent pyrexia and
pruritis were reduced in the ketorolac group compared to placebo.7 Most adverse events were
either mild or moderate in nature. NNH was calculated with a result of -200. Table 5 has
summary of results below.
Table 4: Mean Baseline VAS Scores and Difference in SPID6 Values
Mean Baseline
VAS Score (SEM)

Experimental
Group
Control Group

54.7 (+/- 0.6)
54.1 (+/- 0.9)

SPID6 Values
(SEM)
83.3 (+/- 10.6)

Difference between
SPID6 Values

P-Value

46.1

p=0.007

37.2 (+/-12.9)

Table 5: Comparison of Occurrences in Adverse Events between Ketorolac and Placebo
Control event
rate (CER)
0.98

Experiment
event rate (EER)
0.975

Relative risk
increase (RRI)
-0.005

Absolute risk
increase (ARI)
-0.005

Number needed
to harm (NNH)
-200

In Singla et al.8 study, a total of 321 patients were enrolled in the study and grouped in a
2:1 ratio (ketorolac to placebo, respectively).8 301 patients completed the 2-week follow up at
the termination of the study; 203 patients in the experimental group (95%) and 98 patients in the
placebo group (92%).8 A last observation carried forward approach was taken for the subjects
who withdrew early.8 Demographic differences between the two groups were similar and most
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patients were white, middle-age females undergoing partial or total hysterectomies.8 The
experimental drug contained 31.5 mg of ketorolac in a 15% solution.8 The matched placebo was
contained in an identical meter-pumped container and both groups were administered 100 µL of
solution to each nostril. Subjects were given a kit containing five devices, each containing a
month’s supply of the study drug. All patients had access to a PCA morphine pump for the first
48 hours and then rescue opioid medications as needed. VAS and PID scores were assessed at
multiple time intervals, but only those taken at 20,40, and 60 minutes, and 2,3,4,5, and 6 hours
after the first dose will be used for this analysis.8 PID and SPID scores were analyzed using the
two-way analysis of covariance with the baseline PI score made prior to study as covariate.8 The
SPID6 scores for the experimental group was 117.4 (+/- 7.7) while the SPID6 scores for the
control group was 89.9 (+/- 10.6).8 The difference between the scores was 27.6 (p=0.032 with
95% CI 2.5-52.7).8 Table 6 has a summary of the data below. Safety was also measured through
AE and calculating NNH. The IN ketorolac group had a AE frequency rate of 93% while the
placebo group has a AE frequency rate of 96%.8 Nausea, constipation and vomiting were the
most reported AE between both groups.8 Nasal discomfort, rhinalgia and anemia occurred more
frequently in the ketorolac group compared to placebo, however, there were less incidences of
nausea, constipation, pyrexia and tachycardia in the ketorolac group compared to placebo.8 The
NNH was calculated at -33. Table 7 summarizes results for safety below.
Table 6: Mean Baseline VAS Scores and Difference in SPID6 Values
Mean Baseline
VAS Score (SEM)

Experimental
Group
Control Group

62.5 (+/- 1.6)

SPID6 Values
(SEM)
117.4 (+/- 7.7)

Difference between
SPID6 Values

27.6
60.8 (+/- 1.1)

89.9 (+/-10.6)

P-Value and
CI
p=0.032 with
95% CI 2.552.7
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Table 7: Comparison of Occurrences in Adverse Events between Ketorolac and Placebo
Control event
rate (CER)
0.96

Experiment
event rate (EER)
0.93

Relative risk
increase (RRI)
-0.031

Absolute risk
increase (ARI)
-0.03

Number needed
to harm (NNH)
-33

DISCUSSION
Ketorolac is an accepted adjunctive therapy for acute post-surgical pain management in
adults over 18 years of age. Although opioid medications continue to be first line as stated above,
using multiple modalities of medication may better treat acute postoperative pain to reduce side
effects and decreased quality of life. The IN route allows for easy and quick absorption which
allows patients to administer the medication without the need for an IV catheter.6,7,8 Although
ketorolac is an effective analgesic component for post-surgical treatment, it is not indicated for
all populations. All NSAIDs pose an additional risk to those who have current/past peptic ulcer
disease or gastric bleeding, those at higher risk for cardiovascular thrombosis events, and those
who have decreased or worsening kidney functions.9 Ketorolac is only indicated for maximum 5
days of use in adults and should not be used in chronic pain management.9
All three studies showed a significant pain improvement between the experimental and
control groups (p < 0.05). This could potentially mean that patients who are eligible for ketorolac
could have a significant decrease in pain following a surgical procedure. Benefits of controlling
pain more adequately after a procedure could include shorter hospital stays, decreased sequala,
return to baseline more quickly and less incidences of chronic pain.1,5 Although these studies
focused on inpatient research, limited research is currently available on the use of IN ketorolac in
the outpatient surgical setting. Upon original research for this analysis, only one RCT was found
and this study demonstrated that IN ketorolac was effective in reducing postoperative pain in
patients undergoing outpatient dental procedures.10
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The main limitation to all studies, which may have affected the outcome or limited the
applicability of the results, is the demographics of the study populations. All three studies used in
this analysis primarily included white, middle-aged women undergoing hysterectomies. The
sample size from each study was adequate but may have been too inclusive to a certain
population for the results to be relevant for all surgical patients. Other surgical modalities and
varying demographics were included in each study but not to the same proportion. Additionally,
Moodie et al.6 and Brown et al.7 had a large loss to follow-up (>20%) which could also alter the
impact of the results since the drug may have been given but the research team was unable to
account for the effects and had to accept their last scores taken before withdrawing.
CONCLUSION
The clinical trials included in the analysis demonstrated that IN ketorolac is both
relatively effective and safe in treating acute postoperative pain in a small group of patients over
18 years old. All three studies showed that pain was both better controlled and produced similar
occurrences or even a reduction in AE with IN ketorolac compared to placebo. Further studies
are needed in order to determine if the results carry over to a larger population size that includes
a variety of demographics and/or more common surgical procedures. Further studies are also
warranted to see if IN ketorolac could be applied to an outpatient surgical setting for acute
postoperative pain. Initiating further research to address both limitations could help generalize
the results and help normalize IN ketorolac in general practice so that practitioners could
potentially reduce the massive burden of pain, both physically and financially, on the healthcare
system.

REFERENCES
1. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: A
clinical practice guideline from the american pain society, the american society of regional
anesthesia and pain medicine, and the american society of anesthesiologists' committee on
regional anesthesia, executive committee, and administrative council. J of Pain.
2016;17(2):131-157. https://www.clinicalkey.es/playcontent/1-s2.0-S1526590015009955.
doi: 10.1016/j.jpain.2015.12.008.
2. Gaskin DJ, Richard P. The economic costs of pain in the united states. J of Pain.
2012;13(8):715-724. https://www.clinicalkey.es/playcontent/1-s2.0-S1526590012005597.
doi: 10.1016/j.jpain.2012.03.009.
3. Steiner CA, Karaca Z, Moore BJ, Imshaug MC, Pickens G. Surgeries in hospital-based
ambulatory surgery and hospital inpatient settings, 2014. Medical Benefits. Aug 1,
2017;34:10 Accessed October 02, 2018.
4. Understanding pain; Mayo Clinic web site. https://www.mayoclinic.org/understandingpain/art-20208632. Published July 26, 2016. Accessed October 2, 2018.
5. Klingensmith ME. The washington manual of surgery. 7th ed. Philadelphia: Wolters Kluwer
Health; 2015:15-25, 130-131.
https://ebookcentral.proquest.com/lib/[SITE_ID]/detail.action?docID=4786220.
6. Moodie JE, Colin R Brown, Eileen J Bisley, Hans U Weber, Lincoln Bynum. The safety and
analgesic efficacy of intranasal ketorolac in patients with postoperative pain. Anesthesia and
analgesia. 2008;107(6):2025-2031. http://www.ncbi.nlm.nih.gov/pubmed/19020154. doi:
10.1213/ane.0b013e318188b736.
7. Brown C, Moodie J, Bisley E, Bynum L. Intranasal ketorolac for postoperative pain: A phase
3, double-blind, randomized study. Pain Medicine. 2009;10(6):1106-1114.
http://ezproxy.pcom.edu:2048/login?url=http://search.ebscohost.com.ezproxy.pcom.edu:204
8/login.aspx?direct=true&db=rss&AN=44205862&site=ehost-live&scope=site. doi:
10.1111/j.1526-4637.2009.00647.x.
8. Singla N, Singla S, Minkowitz HS, Moodie J, Brown C. Intranasal ketorolac for acute
postoperative pain. Current Medical Research & Opinion. 2010;26(8):19151923. http://www.ncbi.nlm.nih.gov/pubmed/20557145. doi: 10.1185/03007995.2010.495564
9. Indications and Usage; Sprix Official Website. https://www.sprix.com. Updated 2018.
Accessed December 7, 2018.
10. Grant, George M., DDS, PhD|Mehlisch, Donald R., MD, DDS. Intranasal ketorolac for pain
secondary to third molar impaction surgery: A randomized, double-blind, placebo-controlled
trial. Journal of Oral and Maxillofacial Surgery. 2010;68(5):10251031. https://www.clinicalkey.es/playcontent/1-s2.0-S0278239109019776. doi:
10.1016/j.joms.2009.10.023.

